Document is current
Any future updates will be listed below
-
Authors
A. Avelar, Rita https://orcid.org/0000-0003-4574-3046
Gupta, Riya
Carvette, Grace
da Veiga Leprevost, Felipe
Jasti, Medhasri
Colina, Jose
Teitel, Jessica https://orcid.org/0000-0002-8962-4690
Nesvizhskii, Alexey I.
O’Connor, Caitlin M.
Hatzoglou, Maria
Shenolikar, Shirish
Arvan, Peter
Narla, Goutham
DiFeo, Analisa https://orcid.org/0000-0001-8319-6763
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA197780)
U.S. Department of Defense (OC210149)
U-M | Horace H. Rackham School of Graduate Studies, University of Michigan (N/A)
- License Information
-
More Information
Article History
Received: 4 March 2024
Revised: 4 September 2024
Accepted: 12 September 2024
First Online: 30 September 2024
Competing interests
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of University Hospitals of Cleveland (protocol code UHCMC IRB number: 10-12-06C and approval date of 08/17/2016. Informed consent was obtained from all subjects involved in the study. GN has an equity interest in RAPPTA Therapeutics and GN and CO serves as consultant to RAPPTA Therapeutics. GN serves on the Scientific Advisory Board for HERA Biolabs. All other authors declare no competing interests.
: All methods were performed in accordance with the relevant guidelines and regulations. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of University Hospitals of Cleveland (protocol code UHCMC IRB number: 10-12-06C and approval date of 08/17/2016. Informed consent was obtained from all subjects involved in the study.
